Luteolysis, onset of estrus, and ovulation in Holstein heifers given prostaglandin F2alpha concurrent with, or 24 hours prior to, removal of an intravaginal, progesterone-releasing device.
The objective was to determine the effects of giving prostaglandin F2alpha (PGF) concurrent with, or 24 h before, removal of an intravaginal, progesterone-releasing (controlled internal drug release [CIDR]) device, on luteolysis, the synchrony of estrus and ovulation. Eighteen postpubertal Holstein heifers were given a CIDR and 100 microg gonadotropin releasing hormone (GnRH) and equally allocated to 3 groups. The PGF was given concurrently with CIDR removal after 7 or 8 d (groups D7/D7 and D8/D8, respectively) or given 1-d before removal of CIDR after 8 d (group D7/D8). There was no difference (P > 0.75) among groups in the intervals (h) from CIDR removal to onset of standing estrus and to ovulation (49.3 h+/-6.2 h and 77.5 h+/-9.0 h, respectively; least squares means+/-standard error of means). We also determined if stage of the estrus cycle influenced the synchrony of estrus or ovulation. In heifers in metestrus at CIDR insertion (versus those at estrus or diestrus), intervals from CIDR removal to estrus and to ovulation were longer by 33.4 h (P < 0.05) and 38.5 h (P = 0.01), respectively. However, the interval from standing estrus to ovulation was not affected. Giving PGF concurrent with CIDR removal did not affect luteal regression, the synchrony of estrus, and ovulation; but heifers in metestrus at the initiation of treatment had longer intervals from CIDR removal to estrus and ovulation.
Hittinger
M A
MA
Dairy Research and Technology Centre, Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5.
Ambrose
J D
JD
Kastelic
J P
JP
D000818:Animals; D002417:Cattle / Q000502:physiology*; D003692:Delayed-Action Preparations; D015237:Dinoprost / Q000494:pharmacology*; D004343:Drug Implants; D004971:Estrus / Q000187:drug effects* / Q000502:physiology; D004973:Estrus Synchronization / Q000379:methods; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D003341:Luteolysis / Q000187:drug effects* / Q000502:physiology; D010053:Ovary / Q000000981:diagnostic imaging; D010060:Ovulation / Q000187:drug effects* / Q000502:physiology; D010120:Oxytocics / Q000494:pharmacology*; D013997:Time Factors; D014463:Ultrasonography
D003692:Delayed-Action Preparations; D004343:Drug Implants; D010120:Oxytocics; D007987:Gonadotropin-Releasing Hormone; D015237:Dinoprost